Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Cassava Sciences, Inc. (NASDAQ:SAVA) shares are trading higher Monday. Here’s what you need to know.
What To Know: Cassava Sciences is scheduled to hold a conference call on Thursday, August 8 2024, to discuss recent developments and provide a company update. Analysts expect the company to report an earnings per share (EPS) loss of 40 cents.
Additionally last week, Cassava announced plans to extend its open-label extension trials for simufilam by up to 36 months, allowing patients from previous trials to continue their treatment while awaiting Phase 3 trial results.
In Memoriam: Cassava Sciences also mourns the loss of long-time board member Sanford “Sandy” Robertson, who served on the Board of Directors since the company’s inception as a public entity in 1998.
SAVA Price Action: Cassava Sciences shares were up by 20.9% at $35.20, according to Benzinga Pro.
See Also:
Photo by solarseven on Shutterstock.
Posted In: SAVA